Johns Hopkins Diabetes Guide →Medications →Obesity

Incretin Mimetics and Amylin Analogues

Ana Emiliano, M.D., Brian Pinto, Pharm.D.
Incretin Mimetics and Amylin Analogues is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Incretin mimetics (exenatide, liraglutide, albiglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
  • Liraglutide (Saxenda): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
  • Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: July 17, 2015

Citation

TY - ELEC T1 - Incretin Mimetics and Amylin Analogues ID - 547071 A1 - Emiliano,Ana,M.D. AU - Pinto,Brian,Pharm.D. Y1 - 2015/07/17/ PB - Johns Hopkins Diabetes Guide UR - https://www.unboundmedicine.com/medline/view/Johns_Hopkins_Diabetes_Guide/547071/all/Incretin_Mimetics_and_Amylin_Analogues ER -